WO2001034833A3 - Regulating endogenous inhibitor at atp synthase - Google Patents

Regulating endogenous inhibitor at atp synthase Download PDF

Info

Publication number
WO2001034833A3
WO2001034833A3 PCT/US2000/030862 US0030862W WO0134833A3 WO 2001034833 A3 WO2001034833 A3 WO 2001034833A3 US 0030862 W US0030862 W US 0030862W WO 0134833 A3 WO0134833 A3 WO 0134833A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
atp synthase
mitochondrial atp
endogenous inhibitor
regulating endogenous
Prior art date
Application number
PCT/US2000/030862
Other languages
French (fr)
Other versions
WO2001034833A2 (en
Inventor
Christen M Anderson
William Clevenger
Original Assignee
Mitokor
Christen M Anderson
William Clevenger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokor, Christen M Anderson, William Clevenger filed Critical Mitokor
Priority to AU17599/01A priority Critical patent/AU1759901A/en
Priority to CA002390646A priority patent/CA2390646A1/en
Priority to JP2001536758A priority patent/JP2003527835A/en
Priority to EP00980320A priority patent/EP1230379A2/en
Publication of WO2001034833A2 publication Critical patent/WO2001034833A2/en
Publication of WO2001034833A3 publication Critical patent/WO2001034833A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

The present invention provides compositions and methods for altering mitochondrial ATP production, including binding and functional assays exploiting IF1 interactions with ATP synthase. Also disclosed are methods for screening assays for a compound capable of reducing mitochondrial ATP hydrolysis and/or increasing mitochondrial ATP synthesis, including pharmaceutical compositions identified by such methods. The invention also provides methods for treating diabetes, and in particular, type 2 DM, using an agent identified according to the disclosed methods.
PCT/US2000/030862 1999-11-10 2000-11-10 Regulating endogenous inhibitor at atp synthase WO2001034833A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU17599/01A AU1759901A (en) 1999-11-10 2000-11-10 Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes
CA002390646A CA2390646A1 (en) 1999-11-10 2000-11-10 Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes
JP2001536758A JP2003527835A (en) 1999-11-10 2000-11-10 Regulatory endogenous inhibitors in ATP synthase
EP00980320A EP1230379A2 (en) 1999-11-10 2000-11-10 Regulating endogenous inhibitor at atp synthase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16462299P 1999-11-10 1999-11-10
US60/164,622 1999-11-10

Publications (2)

Publication Number Publication Date
WO2001034833A2 WO2001034833A2 (en) 2001-05-17
WO2001034833A3 true WO2001034833A3 (en) 2002-01-17

Family

ID=22595338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030862 WO2001034833A2 (en) 1999-11-10 2000-11-10 Regulating endogenous inhibitor at atp synthase

Country Status (5)

Country Link
EP (1) EP1230379A2 (en)
JP (1) JP2003527835A (en)
AU (1) AU1759901A (en)
CA (1) CA2390646A1 (en)
WO (1) WO2001034833A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072739A1 (en) * 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
AU2002213424A1 (en) * 2000-09-20 2002-04-02 Mitokor Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter
US7470542B2 (en) 2001-09-05 2008-12-30 Pride Proteomics A/S Proteins in type 2 diabetes
KR102239074B1 (en) * 2018-09-14 2021-04-14 고려대학교 산학협력단 Composition for Preventing or Treating Obesity Comprising IF1
KR102276379B1 (en) * 2018-10-02 2021-07-14 고려대학교 산학협력단 Composition for Preventing or Treating Bone Diseases Comprising IF1
KR102248110B1 (en) * 2018-10-02 2021-05-06 고려대학교 산학협력단 Anti-Cancer Composition Comprising IF1
KR102239075B1 (en) * 2018-10-02 2021-04-14 고려대학교 산학협력단 Composition for Preventing or Treating Sarcopenia Comprising IF1
KR20230135586A (en) * 2021-01-24 2023-09-25 마이클 데이비드 포레스트 ATP synthase inhibitors - cosmetic and therapeutic uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033909A1 (en) * 1997-01-31 1998-08-06 Incyte Pharmaceuticals, Inc. Novel human atpase inhibitor protein
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO2000028041A1 (en) * 1998-11-05 2000-05-18 Microbiological Research Authority Delivery of superoxide dismutase to neuronal cells
US6140067A (en) * 1999-04-30 2000-10-31 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1998033909A1 (en) * 1997-01-31 1998-08-06 Incyte Pharmaceuticals, Inc. Novel human atpase inhibitor protein
WO2000028041A1 (en) * 1998-11-05 2000-05-18 Microbiological Research Authority Delivery of superoxide dismutase to neuronal cells
US6140067A (en) * 1999-04-30 2000-10-31 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROUSLIN WILLIAM ET AL: "Analysis of factors affecting functional assays for estimating IF-1, the mitochondrial ATPase inhibitor.", ANALYTICAL BIOCHEMISTRY, vol. 222, no. 1, 1994, pages 68 - 75, XP002170981, ISSN: 0003-2697 *

Also Published As

Publication number Publication date
JP2003527835A (en) 2003-09-24
EP1230379A2 (en) 2002-08-14
CA2390646A1 (en) 2001-05-17
WO2001034833A2 (en) 2001-05-17
AU1759901A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
WO2002068680A3 (en) Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes
BG104819A (en) Substituted indolealkanoic acids
WO2004084453A3 (en) METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
CA2390867A1 (en) Method for the production of biopolymers with modified properties
WO2003053997A3 (en) Methods of increasing endogenous erythropoietin (epo)
WO2008012542A3 (en) Polysaccharide derivatives of erythropoietin
WO2006100082A3 (en) Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
BG106440A (en) Nitrogen-heterocyclic derivatives as nos inhibitors
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
MY127953A (en) Gabapentin-containing solid compositions and process for preparing the same
AU2003258187A1 (en) Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives
WO2003006070A3 (en) Improved chelator conjugates
WO1998041513A3 (en) Substituted aminosalicyclic acid amides with fungicidal effect and intermediate products for production thereof
BG101892A (en) Sugar-modified cytostatics
WO2001034833A3 (en) Regulating endogenous inhibitor at atp synthase
EA200800785A1 (en) 4-Aryl-1,4-DIHYDRO-3 (2H) -IZOHINOLINONINY and 4-Aryl-in-Service of the Commonwealth of Independent Companies on-line of the Republic of Tatarstan; ON THEIR BASIS AND METHOD OF TREATMENT OF DISEASES MEDIATED BY IGF-1 RECEPTOR
MY138542A (en) Biguanide and dihydrotriazine derivatives
CA2280369A1 (en) A process for the manufacture of hydrophobic paper or hydrophobic board, and a sizing composition
AU2003248647A1 (en) Stereoselective synthesis of 1,2-disubstituted cycloalkyls
TW200720234A (en) Hydroxynaphthalenedicarboxylic acid hydrazide and derivatives thereof as well as process for preparing them
WO1999037291A3 (en) Utilization of substituted sulfonamides as antiviral agents and novel substances
AU1100897A (en) Stabilized antisun compositions
AU1572301A (en) Cyclopentyl sulfonamide derivatives
WO2001051651A3 (en) High expression and production of high-specific activity recombinant s-adenosyl homocysteinase (sahh) and improved assays for s-adenosylmethionine (sam)
AU7399801A (en) Hydantoin derivatives with affinity for somatostatin receptors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2390646

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 536758

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000980320

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000980320

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000980320

Country of ref document: EP